scholarly journals The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1

PLoS ONE ◽  
2017 ◽  
Vol 12 (12) ◽  
pp. e0189060 ◽  
Author(s):  
Linda Sundström ◽  
Susanna Myhre ◽  
Monika Sundqvist ◽  
Andrea Ahnmark ◽  
William McCoull ◽  
...  
Keyword(s):  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

770-P: The Glucose-Lowering Effect of the Bile Acid Sequestrant Sevelamer Is Not Mediated by Glucagon-Like Peptide-1

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 770-P
Author(s):  
HENRIETTE H. NERILD ◽  
ANDREAS BRØNDEN ◽  
DAVID P. SONNE ◽  
JENS J. HOLST ◽  
TINA VILSBØLL ◽  
...  
Keyword(s):  
Bile Acid ◽  
Bile Acid Sequestrant ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

1145-P: Acarbose-Induced Glucagon-Like Peptide-1 Secretion Contributes to the Glucose-Lowering Effect of Acarbose

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1145-P ◽  
Author(s):  
NIELS B. DALSGAARD ◽  
LÆRKE S. GASBJERG ◽  
LAURA S. HANSEN ◽  
NINA L. HANSEN ◽  
SIGNE STENSEN ◽  
...  
Keyword(s):  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin

2016 ◽  
Vol 18 (10) ◽  
pp. 955-961 ◽  
Author(s):  
Emilie Bahne ◽  
Morten Hansen ◽  
Andreas Brønden ◽  
David P. Sonne ◽  
Tina Vilsbøll ◽  
...  
Keyword(s):  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Postprandial glucose-lowering effect of cagaita (Eugenia dysenterica DC) fruit juice in dysglycemic subjects with metabolic syndrome: An exploratory study

2021 ◽  
Vol 142 ◽  
pp. 110209
Author(s):  
Renata Luise de Araujo ◽  
Francisco A. Tomás-Barberán ◽  
Rosa Ferreira dos Santos ◽  
J. Alberto Martinez-Blazquez ◽  
Maria Inés Genovese
Keyword(s):  
Metabolic Syndrome ◽  
Exploratory Study ◽  
Fruit Juice ◽  
Postprandial Glucose ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect ◽  
Eugenia Dysenterica

The Use of SGLT2i and GLP-1 RA in Patients with Type 2 Diabetes in Thailand: Evidence Review and Recommendations

2021 ◽  
Vol 104 (11) ◽  
pp. 1850-1865
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Lowering ◽  
Sodium Glucose Cotransporter ◽  
Evidence Review ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Glucose Lowering Therapy ◽  
The Cost ◽  
Selection Of

Background: Cardiovascular (CV) and renal comorbidities are common among type 2 diabetes (T2D) patients, and significantly increase the cost and burden of care. Both sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve key outcomes including major CV events, hospitalization for heart failure, and renal outcomes, albeit to varying degrees in different T2D populations. Materials and Methods: The authors reviewed evidence from GLP-1 RA and SGLT2i CV outcomes trials and real-world studies in Thailand and elsewhere. Results: The authors formulated recommendations to guide selection of anti-diabetes medication based on patients’ clinical characteristics and CV or renal risk profile. Conclusion: These recommendations could help guide management of CV/renal comorbidities and risk alongside glucose-lowering therapy for individual patients. Keywords: Type 2 diabetes mellitus; Cardiovascular diseases; Chronic kidney disease; Clinical outcomes; SGLT2i; GLP-1 RA

Sign in / Sign up

Export Citation Format

Share Document